- 10X Restriction Enzyme Reaction Buffer 3
- 基因表达载体和病毒
- Prigrow CI Medium
- 1kb Plus Opti-DNA Marker
- 10X Restriction Enzyme Reaction Buffer 2
- 抗体
- PriCoat Flasks
- 细胞生物学
- Prigrow VI Medium
- 2019冠状病毒疾病（Coronavirus Disease 2019）;
- 10X Universal Restriction Enzyme Reaction Buffer
- Prigrow X Series Medium for T5403
- 1kb Opti DNA标记
- miRNA一体化cDNA合成试剂盒
- 100bp Opti-DNA Marker
- 普锐斯系列T0768培养基
- 高保真™ 保真度DNA聚合酶
- PriCoat T75烧瓶，过滤器盖
- 10X Restriction Enzyme Reaction Buffer 1
- Prigrow XII培养基
- 分子生物学和PCR
| Description | dCas9-KRAB is used for CRISPR gene repression (CRISPRi). The Cas9 Double Mutant (dCas9) has changes at amino acid positions D10A and H840A which completely inactivate both the nuclease and nickase activities. In this construct, dCas9 carries a C-terminal Krüppel associated box (KRAB) domain. By targeting dCas9-KRAB to a promoter region, users will be able to specifically repress expression of virtually any gene of interest. This dCas9-KRAB lentiviral vector may be used for either non-viral transfection, or packaged into lentivirus for stable integration of dCas9-KRAB into host cells. Use this dCas9-KRAB lentiviral vector in conjunction with a CRISPRi sgRNA lentiviral vector designed specifically for CRISPR repression. |
|---|---|
| SKU | K203 |
| System | Lentiviral Vector |
| Vector Map | pLenti-EF1a-dCas9-KRAB |
| Unit quantity | 10 µg |
| Promoter | EF1a |
| Cas Type | Null Mutant |
| Cas Origin | spCas9 |
| Cas9 Expression | Constitutive Cas9 |
| Shipping Conditions | Shipped at ambient temperature |
| Bacterial Selection | Kanamycin |
| Format | Vector |
| Appearance | Liquid |
| Quality Control | Restriction Enzyme Digest and Sequencing |
| Shelf Life | 1 year (when at -20°C or below) |
| Caution | This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. |
- Dai, X., Chen, X., Hakizimana, O., & Mei, Y. "Genetic interactions between ANLN and KDR are prognostic for breast cancer survival" Oncology Reports. : (2019).
